Sanofi Pasteur Commercializing MRSA Vaccine

The French vaccine maker announced a worldwide licensing agreement with the biotech company Syntiron to develop and commercialize its vaccine against staph, including Methicillin-resistant Staphylococcus aureus.

Sanofi Pasteur, the vaccines division of the Lyon, France-based sanofi-aventis Group, announced Wednesday it has entered into an exclusive, worldwide licensing agreement with Syntiron of St. Paul, Minn., to develop and commercialize its vaccine against staph, including Methicillin-resistant Staphylococcus aureus (MRSA), which is a major cause of health care-acquired infections.

Sanofi Pasteur will support the joint, pre-clinical development of the product and be responsible for all future developments, regulatory approval, and commercialization of the vaccine. "This agreement with Syntiron is just another example of Sanofi Pasteur's interest in partnering with biotechs to produce innovative vaccines to address public health needs," Sanofi Pasteur President/CEO Wayne Pisano said in the company's news release. "Along with our development of a vaccine to prevent Clostridium difficile infection, the successful development of a vaccine to prevent MRSA would be a major achievement in combating hospital-associated infections."

Citing the Internet Journal of Infectious Diseases, the release said MRSA accounts for as much as 40 percent of nosocomial (hospital-associated) staph infections in large U.S. hospitals and 25-30 percent in smaller hospitals. In Europe, its prevalence ranges from more than 50 percent in Portugal and Italy to below 2 percent in Switzerland and the Netherlands. Prevalence in Asia is about 50 percent, with high rates in Hong Kong (75 percent) and Japan (72 percent), and prevalence in African hospitals is estimated at 15 percent, with Kenya and Nigeria having the highest prevalence of 21-30 percent.

Download Center

  • Safety Metrics Guide

    Is your company leveraging its safety data and analytics to maintain a safe workplace? With so much data available, where do you start? This downloadable guide will give you insight on helpful key performance indicators (KPIs) you should track for your safety program.

  • Job Hazard Analysis Guide

    This guide includes details on how to conduct a thorough Job Hazard Analysis, and it's based directly on an OSHA publication for conducting JHAs. Learn how to identify potential hazards associated with each task of a job and set controls to mitigate hazard risks.

  • A Guide to Practicing “New Safety”

    Learn from safety professionals from around the world as they share their perspectives on various “new views” of safety, including Safety Differently, Safety-II, No Safety, Human and Organizational Performance (HOP), Resilience Engineering, and more in this helpful guide.

  • Lone Worker Safety Guide

    As organizations digitalize and remote operations become more commonplace, the number of lone workers is on the rise. These employees are at increased risk for unaddressed workplace accidents or emergencies. This guide was created to help employers better understand common lone worker risks and solutions for lone worker risk mitigation and incident prevention.

  • EHS Software Buyer's Guide

    Learn the keys to staying organized, staying sharp, and staying one step ahead on all things safety. This buyer’s guide is designed for you to use in your search for the safety management solution that best suits your company’s needs.

  • Vector Solutions

Featured Whitepaper

OH&S Digital Edition

  • OHS Magazine Digital Edition - July August 2022

    July / August 2022

    Featuring:

    • CONFINED SPACES
      Specific PPE is Needed for Entry and Exit
    • HAZARD COMMUNICATION
      Three Quick Steps to Better HazCom Training
    • GAS DETECTION
      Building a Chemical Emergency Toolkit
    • RESPIRATORY PROTECTION
      The Last Line of Defense
    View This Issue